Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475140 | 0.89 | CPT1A (0.46) | GRM5 | |
| SCHEMBL5333014 | 0.88 | GRM5 (0.71) | GRM5HCRTR1HCRTR2MAPTLMNA | |
| SCHEMBL5333005 | 0.88 | GRM5 (0.71) | GRM5HCRTR1HCRTR2MAPTLMNA | |
| SCHEMBL5628484 | 0.87 | GRM5 (0.72) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL5956222 | 0.87 | GRM5 (0.50) | GRM5USP30 | |
| SCHEMBL5955709 | 0.85 | GRM5 (0.57) | GRM5HCRTR1HCRTR2MAPTLMNA | |
| SCHEMBL5475778 | 0.84 | USP30 (0.47) | GRM5HCRTR1HCRTR2USP30 | |
| SCHEMBL5478169 | 0.83 | USP30 (0.56) | GRM5MAPTSMN1; SMN2USP30 | |
| SCHEMBL5329418 | 0.83 | GRM5 (0.54) | GRM5HCRTR1HCRTR2MAPTLMNA | |
| SCHEMBL5475009 | 0.80 | GRM5 (0.51) | GRM5HCRTR1HCRTR2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1716143-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-02-02 | — | — | US | disclosed |
| WO-2005080386-A1 | POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025414-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | GRM5 5/4885HCRTR1 109/4885HCRTR2 140/4885 |
| US-20070185100-A1 | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRM1, GRM4 | GRM5 4/4885HCRTR1 113/4885HCRTR2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.